Mubadala Capital Joins $200M Investment in Tenvie Therapeutics

Mubadala Capital, a UAE-based investment firm, has participated in a $200 million funding round for Tenvie Therapeutics, a San Francisco-based biotechnology company. The investment, which also includes contributions from ARCH Venture Partners and F-Prime Capital, aims to accelerate Tenvie's growth into a multi-clinical asset company.

Tenvie Therapeutics, launched on January 8, 2025, focuses on advancing treatments for neurological, cardiometabolic, and ophthalmic diseases. The company's mission is to fundamentally change the treatment paradigm for neurological conditions and significantly impact patients' lives.

1. Funding: $200 million raised from Mubadala Capital, ARCH Venture Partners, F-Prime Capital, and other investors.

2. Company focus: Developing innovative treatments for neurological, cardiometabolic, and ophthalmic diseases.

3. Expert team: Tenvie has assembled specialists in neurology, CNS development, small molecule chemistry, and translational medicine.

4. Board addition: Alaa Halawa from Mubadala Capital joins Tenvie's Board of Directors.

5. Industry perspective: Stacie Weninger of F-Prime Capital expressed confidence in Tenvie's potential to lead the next generation of neurology treatments.

--

Join the Future of Venture Capital Investing with Newnex

Newnex is the platform focused on institutional investors where verified startups, VCs, and LPs converge for private fundraising and investment through trusted references. Centralize your fundraising and investment activities and access the global VC network with just a few clicks. Join for free at www.newnex.io 

We are digitalizing institutional investing to make VC as accessible as public markets while retaining the uniqueness of private markets. The mission is to unify 5,000+ VC/LP firms with 100,000 startups on a trusted platform for reference-only private deal-making.

Disclaimer: The information presented in this article is based on available sources and may not be entirely accurate or up-to-date. We do not guarantee the accuracy of the content, and readers should conduct their own research and consult with financial professionals before making any decisions.